drugset / Trial / NCT06435221

Safety Study of Cytisinicline in Adult Combustible and/or E-cigarette Smokers

NCT06435221

Phase 3 Completed 479 enrolled Achieve Life Sciences
NaSingle-groupOpen-labelTreatment

Summary

Safety assessment of long-term 3 mg cytisinicline three times daily (TID) exposure for 52 weeks is the main purpose of this study, conducted in the United States.

Timeline

Start
2024-05-28
Primary completion
2025-09-29
Completion
2025-10-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Cytisinicline Small molecule 3 mg Oral

Indications

No indication recorded.